Factors affecting delivery of antiviral drugs to the brain.
about
Inhibition of West Nile Virus Multiplication in Cell Culture by Anti-Parkinsonian DrugsBarriers to HIV Cure.Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.HIV, dementia and antiretroviral drugs: 30 years of an epidemic.Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.Transport and metabolism at blood-brain interfaces and in neural cells: relevance to bilirubin-induced encephalopathy.HIV infection and the central nervous system: a primer.Drug interactions at the blood-brain barrier: fact or fantasy?Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous systemDevelopment of a physiologically-based pharmacokinetic model of the rat central nervous system.How much do antiretroviral drugs penetrate into the central nervous system?CSF penetration by antiretroviral drugs.Efflux transporters in blood-brain interfaces of the developing brainThe Role of HIV Infection in Neurologic Injury.Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.Exploration of 3,6-dihydroimidazo(4,5-d)pyrrolo(2,3-b)pyridin-2(1H)-one derivatives as JAK inhibitors using various in silico techniques.Exploring the chemical space of aromatase inhibitors.Brain protection at the blood-cerebrospinal fluid interface involves a glutathione-dependent metabolic barrier mechanism.2D-QSAR Study of Indolylpyrimidines Derivative as Antibacterial againstPseudomonas aeruginosaandStaphylococcus aureus: A Comparative Approach
P2860
Q24273361-3D9053C3-B6DC-418D-9385-27304753140EQ30245414-836095CB-1025-4CC3-9B0D-729C920636F2Q33946973-9491174F-6B16-4225-BE0D-256CC1E5791DQ34573511-52F4388A-D243-4F5F-AE03-CB5A571FC88EQ35823231-C0E49834-BB0B-4010-A91E-8433D86049B5Q35969947-CFFB843D-4157-4B36-BD60-026D14C63C83Q37213342-D58A102C-3BBF-4E92-8378-5084651D5DDEQ37362486-96A23425-458E-4607-97FD-C75880B51DE5Q37390163-C8742409-E660-4BF9-97A1-581A776DD69EQ37689854-ADBFADEC-7591-4BD6-A40F-374A887C1390Q38003612-483D7CA4-95BE-401C-A051-274FC79B35BBQ38060571-F2A8E5B0-1DEE-4A8B-9CE0-55EC2A5696A8Q38362582-04424123-1092-4FD4-98E7-AACB6CA313E1Q39224160-D5481EC1-0AE9-43C4-8C48-43D4A06531CAQ42262319-25951B29-8F65-4C7D-9F27-AB873DB69CE6Q42702064-7576BAFD-C655-4010-A492-17585CC47E26Q45191655-ECD69B25-44A9-4147-8D41-4FA22838C2F9Q46881152-8DA6F07D-B6CE-4D42-A3E2-3A4A1A982C15Q59051570-C6A7DE90-7ECE-46D7-AE9A-BD82A5E1DDF9
P2860
Factors affecting delivery of antiviral drugs to the brain.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Factors affecting delivery of antiviral drugs to the brain.
@ast
Factors affecting delivery of antiviral drugs to the brain.
@en
type
label
Factors affecting delivery of antiviral drugs to the brain.
@ast
Factors affecting delivery of antiviral drugs to the brain.
@en
prefLabel
Factors affecting delivery of antiviral drugs to the brain.
@ast
Factors affecting delivery of antiviral drugs to the brain.
@en
P2860
P356
P1476
Factors affecting delivery of antiviral drugs to the brain.
@en
P2093
Jean-François Ghersi-Egea
Nathalie Strazielle
P2860
P304
P356
10.1002/RMV.454
P577
2005-03-01T00:00:00Z